Preclinical assessment of pharmacokinetics and anticonvulsant activity of CBDTech, a novel orally administered cannabidiol (CBD) formulation for seizure and epilepsy

Abstract Oral cannabidiol (CBD) product use is increasing despite suboptimal pharmacokinetics (PK) of currently available formulations. This study aimed to investigate the PK of CBD formulated using the drug delivery technology DehydraTECH™, which is hypothesized to increase absorption by bypassing...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Jacob D. McDonald, Feng Zhou, Justyna Kulpa, Philip J. Kuehl
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2025-09-01
Schriftenreihe:	Journal of Cannabis Research
Schlagworte:	Cannabidiol CBD PK Absorption Bioavailability Brain
Online-Zugang:	https://doi.org/10.1186/s42238-025-00322-7
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!